NOVEL PEPTIDES FOR USE IN TREATMENT OF T-CELL MEDIATED CARTILAGE DESTRUCTION IN AUTOIMMUNE DISEASES

Abstract: The invention relates to the use of novel peptides in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases, more specifically arthritis. The invention furthermore embraces pharmaceutical compositions comprising said peptides and a diagnostic method for the detection of autoreactive T cells in a test sample, said T cells being associated with T-cell mediated articular cartilage destruction in autoimmune diseases and test kits to be used in said method.

Description: Novel Peptides For Use In Treatment Of T-Cell Mediated Cartilage Destruction In Autoimmune Diseases The invention relates to novel peptides and their use in treatment of T-cell mediated articular cartilage destruction in autoimmune diseases. More specifically, the invention relates to the use of said novel peptides in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases, more specifically arthritis and in particular reumatoid arthritis. The invention furthermore embraces pharmaceutical compositions comprizing said peptides and a diagnostic method for the detection of autoreactive T cells in a test sample, said T cells being associated with T-cell mediated articular cartilage destruction in autoimmune diseases and test kits to be used in said method. The immune system is based on the discrimination between foreign antigens (non- self antigens) and autoantigens (self-antigens, derived from the individuals own body) achieved by a build in tolerance against the autoantigens. The immune system protects individuals against foreign antigens and responds to exposure to a foreign antigen by activating specific cells such as T- and B lymphocytes and by producing soluble factors hke cytokines, antibodies and complement factors. The antigen to which the immune system responds is processed by the antigen presenting cells (APCs) and a fragment of the antigen is expressed on the cell surface associated with a major histocompatibility complex (MHC) class II glycoprotein. The MHC-glycoprotein-antigen- fragment complex is presented to a T cell which by virtue of its T cell receptor recognizes the antigen fragment conjointly with the MHC class II protein to which it is bound. The T cell becomes activated, i.e. proliferates and/or produces cytokines, resulting in the expansion ofthe activated T cells directed to the antigen under attack (Grey et al., Sci. Am., 261:38-46, 1989). Self antigens are also continuously processed and presented as antigen fragments by the MHC giycoproteins to T cells (Jardetsky et al., Nature 153:326-329, 1991). Under normal circumstances the immune system is tolerant to self antigens and activation of the immune response by these self antigens is avoided. Thus, self recognition is intrinsic to the immune system. When tolerance to self antigens is lost, the immune system becomes activated against one or more self antigens, resulting in the activation of autoreactive T cells and the production of autoannbodies. This phenomenon is referred to as autoimmunity. As lhe immune response in general is destructive, i.e. meant to destroy the invasive foreign antigen, autoimmune responses can cause destruction o the body's own tissue. The contribution of T cells to autoimmune diseases has been established by several studies. In mice, experimental autoimmune encephalomyelitis (EAE) is mediated by a highly restricted group of T cells, linked by their specificity for a single epitope of myelin basic protein (MBP) complexed to an MHC class II molecule. In the Lewis rat, a species with high susceptibility to various autoimmune diseases, disease has been shown to be mediated by T cells. In humans autoimmune diseases are also thought to be associated with the development of auto-aggressive T cells. A destructive autoimmune response has been implicated in various diseases such as rheumatoid arthritis (RA), in which the integrity of articular cartilage is destroyed by a chronic inflammatory process resulting from the presence of large numbers of activated lymphocytes and MHC class π expressing cells. The mere presence of cartilage appears to be sufficient for sustaining the local inflammatory response: it has been shown that cartilage degradation is associated with the activity of cartilage-responsive autoreactive T cells in RA (Sigall et al, Clin. Exp. Rheumat. 6:59, 1988; Giant et al., Biochem. Soc. Trans. 18:796, 1990; Burmester et al., Rheumatoid arthritis Smolen, Kalden, Maini (Eds) Springer-Verlag Berlin Heidelberg, 1992). Furthermore, removal of cartilage from RA patients by surgery was shown to reduce the inflammatory process. The cartilage proteins are therefore considered to be target autoantigens which are competent of stimulating T cells. Activation of these autoreactive T cells leads to development of autoimmune disease. The inflammatory response resulting in the destruction of the cartilage can be treated by steroid drugs. However, these drugs are immunosuppressive drugs that are nonspecific and have toxic side effects. The disadvantages of nonspecific immunosuppression makes this a highly unfavourable therapy. An antigen-specific, nontoxic immunosuppression therapy would provide a very attractive alternative for the nonspecific immunosuppression. This antigen-specific therapy involves the treatment of patients with MHC Class II binding T-cell reactive peptides derived from the autoantigen. These MHC Class II binding T-cell reactive peptides correspond to T cell epitopes ofthe target autoantigen and can be used to induce specific T cell tolerance both to tiie administered peptides and the autoantigen. To effectively use the peptide-induced tolerance therapy to treat the T cell mediated articular cartilage destruction, there is a great need for MHC Class π binding T cell-reactive peptides which can desensitize patients against the self antigen that is activating the T cells responsible for the inflammatory process. The present invention provides for such MHC Class II binding T-cell reactive peptides, that are suitable for use in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated cartilage destruction in autoimmune diseases. More specifically, the present invention provides MHC Class II binding T-cell reactive peptides which are very suitable for use in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T- cell mediated cartilage destruction in arthritis, in particular reumatoid arthritis. The peptides according to the invention have an amino acid sequence of 13 to 55 amino acid residues, characterized in that said peptides comprise at least the amino acid sequence (SEQ ID No.l) AGWLRιDR 2 R 3 R4R 5 YPI in which Ri is A or S; R 2 is Q, R or G; R 3 is T or S; t is V or L; and R5 is R or Q. More specifically, the peptides according to the invention comprise the amino acid sequence (SEQ ID No:2) AGWLR,DR 2 R 3 LR 5 YPI in which Ri is A or S; R 2 is Q, R or G; R? is T or S; and R5 is R or Q. In particular, the peptides according to the invention comprise at least one of the amino acid sequences AGWLADQTVRYPI (SEQ ID No:3), AGWLADRSVRYPI (SEQ ID No:4), AGWLADGSLRYPI (SEQ ID No:5) or AGWLSDGSVQYPI (SEQ ID No:6) or combinations thereof. Preferably the peptides according to the invention have an amino acid sequence of 13-35 amino acid residues, more preferably 13-25 amino acid residues. Highly preferred are peptides having an amino acid sequence of 13-19 residues. Particularly preferred are the peptides consisting of amino acid sequence AGWLADQTVRYPI (SEQ ID No:3), AGWLADRSVRYPI (SEQ ID No:4), AGWLADGSLRYPI (SEQ ID No:5) and AGWLSDGSVQYPI (SEQ ID No:6). The peptides according to the invention are also understood to comprise multimers, such as for example a dimer or a trimer, which are build up from monomeric building blocks formed by the peptides according to the invention. These monomeric building blocks optionally can be separated by spacer residues. The multimers according to the invention have the advantage that they provide a multitude of T-cell reactive peptides. The present invention resides in the fact that the peptides according to the invention resemble MHC Class II binding T-cell epitopes present on autoantigenic proteins which are constituents of the human articular cartilage. More specifically, the peptides according to the invention resemble MHC Class II binding T-cell epitopes present on the large aggregating proteoglycan of human articular cartilage, human aggrecan (HAG) and human cartilage link protein (HCLP). It was suφrisingly found that the amino acid residues 201-213, 299-311 and 623- 635 ofthe primaiy structure of HAG (starting from the methionine in the signal sequence) as well as the amino acid residues 207-219 ofthe primary structure of HCLP (starting from the methionine in the signal sequence) display MHC Class II binding T-cell epitopes which are recognized by cartilage-responsive autoaggressive T cells associated with the destruction of articular cartilage in autoimmune diseases, more specific arthritis, in particular reumatoid arthritis. The primary structures of HAG and HCLP have been described in Doege et al., J. Biol. Chem. Vol. 266, no. 2: 894-902 (1991) and Dudhia et al., Nucl. Acid Res., Vol. 18, no. 5: 1292 (1990) respectively. Although articular cartilage proteins are considered to be the target autoantigens competent of stimulating autoaggressive T cells involved in the destruction of articular cartilage in autoimmune diseases, it was not untill the present invention that these MHC Class II binding T-cell epitopes associated with cartilage-responsive autoreactive T cells have been identified on the cartilage proteins, in particular on HAG and HCLP. The peptides according to the invention resemble these MHC Class II binding T-cell epitopes, thus providing T-cell reactive peptides which can be used in the peptide-induced T-cell tolerance therapy. Accordingly, patients can be treated with the peptides according to the invention to induce specific T-cell tolerance not only to the administered peptides but to the target autoantigens HAG and HCLP as wel. As other components of the immune system are not affected by the peptides according to the invention, the immune system of the patient will remain intact and will be able to protect the patient against other infections. Thus, the peptides according to Λe invention provide a very attractive altemative for the classic steroid drugs in the treatment of T-cell mediated destruction of articular cartilage in autoimmune diseases, more specific arthritis, in particular reumatoid arthritis. Peptides according to the invention have been described. Perin et al, FEBS Letters 206:73 (1986) describes the structural relationship between link proteins and proteoglycan monomers and discloses a peptide fragment obtained after tryptic digestion of the link protein. The peptide fragment has the amino acid sequence SSAGWLADRSVRYPISKARPNXGG. Goetinck et al, J. Cell Biol. 105:2403-2408 (1987) discloses the peptides NAGWLSDGSVQYPITKPREP and DAGWLADGHSVRYPISRPRKR which correspond to the amino acid residues Asn 207 - Pro and Asp -Arg respectively of the primary structure of link protein. Said peptides were synthesized to study the interactions between link protein and hyaluronic acid and said amino acid residues were found to be involved in the binding of link protein to hyaluronic acid. Neame et al, J. Biol. Chem. 261(8):3519-3535. (1986) describes the elucidation ofthe primary structure of link protein from rat chondrosarcoma proteglycan aggragate. Analysis of a triptic digest of the link protein revealed a fragment having the amino acid sequence GGLDWCNAGWLSDGSVQYPITKPR Perides et al, J. Biol. Chem., Vol. 264, no. 10: 5981-5987 (1989) describes the isolation and partial characterization of a glial hyaluronate- binding protein (GHBP). Tryptic digestion of GHBP results in several peptide fragments, one of which having the amino acid sequence EQLFAAYEDGFEQCDAGWLADQTVRYPIRAPRVGCY. None of these publications however disclose that said peptides display MHC Class II binding T-cell epitopes which are recognized by cartilage-responsive autoaggressive T cells involved in the destruction of articular cartilage in immune diseases. Nor do these publications suggest or hint towards the use of said peptides in a peptide- induced T-cell tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated destruction of the articular cartilage in autoimmune diseases. The peptides according to the invention can be prepared by well known organic chemical methods for peptide synthesis such as, for example, solid-phase peptide synthesis described for instance in J. Amer. Chem. Soc. 85:2149 (1963) and Int. J. Peptide Protein Res. 35:161-214 (1990). The peptides according to the invention can also be prepared by recombinant DNA techniques. A nucleic acid sequence coding for a peptide according to the invention or a multimer of said peptides is inserted into an expression vector. Suitable expression vectors are, amongst others, plasmids, cosmids, virusses and YACs (Yeast Artificial Chromosomes) which comprise the necessary control regions for replication and expression. The expression vector can be brought to expression in a host cell. Suitable host cells are, for instance, bacteria, yeast cells and mammalian cells. Such techniques are well known in the art, see for instance Sambrooke et al, Molecular Cloning:a Laboratory Manual, Cold Spring Harbor laboratory Press, Cold Spring Harbor, 1989. According to the invention, patients suffering from T-cell mediated destruction of the articular cartilage can be treated with a therapeutical composition comprizing one or more peptides according to the invention and a pharmaceutical acceptable carrier. Administration of the pharmaceutical composition according to the invention will induce tolerance of the specific autoreactive T cells of these patients to the autoantigenic proteins in the articular cartilage under attack and other self antigens which display the identified MHC Class π binding T cell epitopes characterized by one of the amino acid sequences of SEQ ID NO: 1-6. More specifically, administration of the pharmaceutical composition according to the invention will induce tolerance ofthe specific autoaggressive T cells to the autoantigens HAG end HCLP. The induced tolerance thus will lead to a reduction of the local inflammatory response in the articular cartilage under attack. Very suitable peptides to be used in a pharmaceutical composition according to Λe invention are the peptides having 13-55, preferably 13-35, more preferably 13-25, highly preferably 13-19 amino acid residues characterized in Λat said peptides comprise at least one of Λe amino acid sequences given in SEQ ID NO: 1 and 2. Specifically preferred in a pharmaceutical composition according to Λe invention are Λe peptides having 13-55, preferably 13-35, more preferably 13-25, highly preferably 13-19 amino acid residues characterized in Λat said peptides comprise at least one of Λe amino acid sequences given in SEQ ID NO:3-6. Highly preferred in a pharmaceutical composition according to Λe invention are peptides having 13 amino acid residues characterized in that said peptides have Λe amino acid sequence given in SEQ ID NO: 1 and 2. Most preferred in a pharmaceutical composition according to Λe mvention are Λe peptides having 13 amino acid residues wiΛ amino acid sequence of SEQ ID NO: 3, 4, 5 or 6. The peptides according to Λe invention have Λe advantage Λat Λey have a specific effect on Λe autoreactive T cells Λus leaving Λe oΛer components of Λe immune system intact as compared to Λe nonspecific suppressive effect of Λe immunosuppressive steroid drugs. Treatment wiΛ Λe peptides according to Λe invention will be safe and no toxic side effects will occur. Tolerance can be attained by administering high or low doses of peptides according to Λe mvention. The amount of peptide will depend on Λe route of administration, Λe time of administration, Λe age of Λe patient as well as general healΛ conditions and diet. In general, a dosage of 0.01 to 1000 μg of peptide per kg body weight, preferably 0.5 to 500 μg, more preferably 0.1 to 100 μg of peptide can be used. Pharmaceutical acceptable carriers are well known to Λose skilled in Λe art and include, for example, sterile salin, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil and water. OΛer carriers may be, for example MHC class II molecules, if desired embedded in liposomes. In addition Λe pharmaceutical composition according to Λe mvention may comprise one or more adjuvants. Suitable adjuvants include, amongst oΛers, aluminium hydroxide, aluminium phosphate, amphigen, tocophenols, monophosphenyl lipid A, muramyl dipeptide and saponins such as Quill A. The amount of adjuvant depends on Λe nature of Λe adjuvant itself. Furthermore Λe pharmaceutical composition accordmg to Λe invention may comprise one or more stabilizers such as, for example, carbohydrates including sorbitol, mannitol, starch, sucrosedextrin and glucose, proteins such as albumin or casein, and buffers like alkaline phosphates. Suitable administration routes are intramuscular injections, subcutaneous injections, intravenous injections or intraperitoneal injections, oral administration and nasal sprays. The peptides according to Λe mvention are also very suitable for use in a diagnostic meΛod to detect Λe presence of activated autoreactive T cells mvolved in Λe chronic inflammation and destruction of Λe articular cartilage. The diagnostic meΛod accordmg to Λe mvention comprises Λe following steps: a) isolation of Λe peripheral blood mononuclear cells (PBMC) from a blood sample of an mdividual, b) culture said PBMC under suitable conditions, c) incubation of said PBMC culture in Λe presence of Λe autoantigen or one or more peptides derived Λereof according to Λe mvention, and d) detection of a response of T cells, for example a proliferative response, indicating Λe presence of activated autoreactive T cells in Λe mdividual. The detection of a proliferative response of T cells can be detected by, for example, Λe incoφoration of -1H-Λymidine. Also within Λe scope of Λe mvention are test kits which comprise one or more peptides according to Λe invention. These test kits are suitable for use in a diagnostic meΛod according to Λe mvention. The following examples are illustrative for Λe invention and should in no way be inteφreted as limiting Λe scope of Λe invention. EXAMPLES METHODS Patients Peπpheral blood mononuclear cells (PBMC) from patients who were diagnosed as suffering from RA accordmg to Λe Ameπcan Rheumatism Association (ARA) cπteπa (Arnett et al , Arthπtis Rheum 3 315, 1988) were collected The seventy of disease of RA patients ranged from stage I - IV as determmed by Rontgenscore Dunng Λe course of studies patients were treated wiΛ indomeΛacine, meΛotrexate, glucocorticoids or non- steroidal anti-mflammatory drugs MHC typing Patient PBMC chromosomal DNA extracts were analysed usmg Λe Dynal DR 'low resolution' SSP kit DR4 subtypmg was performed usmg Λe Dynal DRB1*04-SSP kit Inteφretation of MHC typmg data was done in collaboration with Λe University Transfusion service, Radboud hospital, Nijmegen, The NeΛerlands Peptides Peptides accordmg to Λe mvention and a control peptide HiA(307-319)F, PKFVKQNTLKAT (SEQ ID NO 7), were synΛesized by sohd-phase peptide synΛesis In bπef, peptides with free ammo- and carboxy termini were synΛesized on a fully automated Mil gen 9050 synΛesizer, usmg Fmoc/tBu protected activated esters on PEG-PS resins The peptides were cleaved off Λe resm and deprotected usmg TFA/Thioamsole/EΛanediΛiol/Amsole 90/5/3/2 or TFA/H 2 O 95/5 by volume The peptides were puπfied by preparative HPLC, converted mto acetate salts wiΛ Dowex Ac- resin or mto chloπde salts and lyophilized Punty and identity of Λe peptides were asssessed by reverse phase HPLC and FAB-MS, respectively The peptides used m this study are listed in Table 1 An N-teπrunal biotinylated Influenza Haemagglutimne deπved peptide IHA(307-319)F, in which Λe third residue (Y) was replaced by F, (biotin-NH- (CH 2 ) 5 -CO-PKFVKQNTLKLAT, SEQ ID No 7), was used as marker peptide in Λe binding studies with DR4Dw4 (DRB 1*0401) In order to prevent interference ofthe biotin group with peptide bmdmg, biotin was attached via a spacer to Λe amino-terminus of Λe marker peptide Table 1 : Λe peptides synΛesized Peptide Sequence HPLC purity SEQ ID NO HAG1 AGWLADQTVRYPI > 90% 3 HAG2 AGWLADRSVRYPI > 90% 4 HAG3 AGWLADGSLRYPI > 90% 5 HCLP1 AGWLSDGSVQYPI > 90% 6 IHA(307-319)F PKFVKQNTLKLAT > 90% 7 Affinity purification of HLA-DR molecules Two EBV-transformed B-cell lines, BSM (typed as DR4 [DRB 1 *0401 ] and BM92 (typed as DR4 [DRB 1*0404) were provided by Dr. M. Oudshoorn from Λe Academic Hospital Leiden, Λe NeΛerlands. The cells were cultured in Dulbecco's modified eagles minimal essential medium DMEM HAM's F12 (Gibco Laboratories, Grand Island, NY) supplemented wiΛ 10% FCS (Hyclone Laboratories), 1% non-essential amino acids (ICI), L-glutamine, 2-ME and antibiotics. Cells were routinely passaged every 2-3 days in a 1:2 ratio. Cells were harvested and Λereafter washed three times in phosphate buffer saline (PBS) (4°C) containing 1 mM PMSF. Cell pellets were stored at -70°C until use. HLA-DR expressmg cells were Λawed and lysed on ice for 30 minutes in PBS, 1% NP-40, 1 mM AEBSF (Calbiochem). The lysate was cleared of nuclei and debris by centrifugation at 15.000 φm (Sorvall, SS34 rotor) for 30 minutes. HLA-DR molecules were affinity purified from cell lysates using monoclonal antibody L243 (ATCC), directed against a nonpolymoφhic determinant on Λe DR- complex (Lampson et al., J. Immunol. 125:293, 1980). Protein G sepharose purified L243 was coupled to NHS-Sepharose 4 FF (Pharmacia) according to Λe manufactures instructions. The cleared cell-lysate was passed through a 0.45 μm filter and added to L243-NHS-sepharose beads. After ovemight incubation, Λe beads were transferred to a column and washed with five volumes PBS, 1% NP-40; 5 volumes PBS, 0.5% NP-40; 15 volumes PBS, 0.5% NP-40, 0.1% SDS; 5 volumes PBS, 0.05% NP-40; 5 volumes PBS, 1% n-octyl-glucoside (Sigma, St. Louis, USA) and 5 volumes 50 mM dieΛylamine (Fluka), 150 mM NaCl, 1% n-octyl-glucoside pH=8.0. HLA-DR molecules were eluted wiΛ 50 mM dieΛylamine, 150 mM NaCl, 1% n-octyl-glucoside pH=l 1. Immediately after collection, the fractions were neutralised wiΛ 2M glycine pH=4.8. Collected fractions were analysed on SDS-PAGE under non-reducing conditions followed by silver staining. Fractions containing purified HLA-DR were pooled and subsequently concentrated by ultrafiltration over a 30 kD cut-off membrane. Peptide HLA-DR binding assay The peptide bmding studies were performed usmg a semi-quantitative bmding assay as described previously (Joosten et al., Int. Immunol. 6:751, 1994). Purified HLA-DR molecules (0.05-5 μM) were incubated at pH=5.0 wiΛ 50 nM biotinylated marker peptide (IHA(307-319)F) and a concentration range of competitor peptide (peptides HAGl, HAG2, HAG3 and HCLPl) in a final volume of 25 μl bmding buffer (PBS, 1 mM AEBSF, 1 mM N-eΛyl maleimide, 8 mM EDTA, 10 μM pepstatin A, 0.01% NaN 3 , 0.05% NP-40 and 5% DMSO). After approximately 48 hours incubation at room temperature, bound and unbound marker peptides were separated by SDS-PAGE under non-reducing conditions. Protems were blotted onto a nitro-cellulose membrane (Hybond ECL, Amersham, U.K.) using a semi-dry blotting system (Pharmacia). The nitrocellulose filters were blocked wiΛ 0.5% DNA blocking reagents (Boehringer Mannheim, Germany) in 0.1 M maleic acid pH=7.5, 150 mM NaCl. After 1 hour, Λe filters were washed in PBS, 0.05% Tween 20 (Sigma, St. Louis, USA) and incubated wiΛ Streptavidin-HRP (SouΛern Biotechnology) in a 1 :40.000 dilution. Biotinylated peptides were detected by enhanced chemoluminescence using a Westem Blot ECL kit (Amersham, U.K.) according to Λe manufactures instructions. Preflashed films (hyperfilm-ECL, Amersham, U.K.) were exposed for 30 minutes. The affinity of a Λe peptides according to Λe invention for bmding DRB1 *0401 or DRBl*0404-encoded molecules was related to competition wiΛ Λe marker peptide. This relative binding affimty IC50 ( e IC5o) was defined as Λe peptide concentration at which Λe signal of Λe biotinylated marker peptide was reduced to 50% by visual inspection of Λe signal in absence of Λe competitor peptide. Proliferative responses of blood mononuclear cells The peptides HAGl, HAG2, HAG3 and HCLPl were tested for Λeir capacity to induce proliferative responses in PBMC. Proliferative assays involving PBMC have been used previously to measure activation of antigen-specific, class II restricted T-cell responses (Good et al, Proc. Natl. Acad.Sci USA 85:1199, 1988) PBMC obtained from heparinized venous peripheral blood were isolated by standard centrifugation on a Ficoll-Paque gradient. Cells were cultured in three- or four¬ fold at a concentration of 1,5 x 10^ cells/well in DMEM/Ham's F12 medium supplemented wiΛ 10% heat-inactivated pooled human serum, L-glutamine, 2-ME and antibiotics in flatbottomed microtiter plates. Cells were mcubated in medium alone or in Λe presence of PHA (2.5 μg/ml) or in Λe presence of antigens, including Λe chicken proteoglycan fraction, Λe chicken collagen fraction, sonicated Mycobacterium tuberculosis or Λe peptides HAGl, HAG2, HAG3 and HCLPl in concentrations of 50 μg/ml, 5μg/ml or 0.5 μg/ml. Cultures were incubated in a total volume of 210 μl for 4, 5, 6 or 7 days at 37 °C in a humidified atmosphere of 5% CO2. Cultures were pulsed with 0.5μCi (1.85 x IO 4 Bq) [ 3 H]Thymidine ([ 3 H]TdR) for Λe last 18 hours of cell culture. Cells were harvested on glassfibre filters and [3H]TdR incoφoratiopn was measured by gasscintilation. Note Λat counting by gasscintilation is fivefold less efficient compared to liquid scintilation. Therefor, filters were measured for 5 min (Packard Matrix 96 β-counter; Meriden CT). RESULTS Peptide HLA-DR binding assay Binding of Λe peptides HAGl, HAG2, HAG3 and HCLPl to DR4 (DRB 1*0401) and DR4(DRB 1*0404) was performed in a direct semi-quantitative competition bmding assay using affinity purified HLA-DR molecules The resits are shown in Table 2.. As can be seen from Table 2, all peptides bind to DR4(DRB 1*0401) ana are able to compete wiΛ Λe marker peptide. Table 2: Peptide binding to HLA-DRB 1*0401 encoded molecules Peptide Sequence DRB1*0401 HAGl AGWLADQTVRYPI -H- HAG2 AGWLADRSVRYPI -H- HAG3 AGWLADGSLRYPI ++ HCLPl AGWLSDGSVQYPI + ++ = good binder, e ICso between 1-10 μm; + = intermediate binder, e ICso between 10-100 μM; +/- = poor binder, e ICso between 100-1000 μM; - = non-binder, e ICso exceeds 1000 μM PBMC proliferative assay In order to determine T-cell reactivity to Λe peptides HAGl, HAG2, HAG3 and HCLPl, Λe PBMC proliferative response in RA patients was analyzed. Table 3 only represents Λe values obtained at 50 μg/ml. Results are expressed as Λe mean of Λree or four measurements (count per 5 min). Standard error of Λe mean did not exceed 30%. Underlined values are regarded positive (counts per 5 min > 1000 and stimulation index SI > 2)). Most patients responded to at least one of Λe peptides according to Λe mvention, indicating Λat Λe peptides accordmg to Λe invention are recognized by autoaggressive T- cells associated with autoimmune disease. Table 3: Proliferative responses of PBMC from RA patients to Λe peptides. ND = not one, BG = ac groun SEQUENCE LISTING (1) GENERAL INFORMATION: (l) APPLICANT: (A) NAME: AKZO NOBEL N.V. (B) STREET: Velperweg 76 (C) CITY: Arnhem (E) COUNTRY: The netherlands (F) POSTAL CODE (ZIP) : 6824 BM (G) TELEPHONE: 04120-66376 (H) TELEFAX: 04120-50592 (I) TELEX: 37503 a pha nl ( i) TITLE OF INVENTION: Novel Peptides For Use In Treatment Of T- Cell Mediated Cartilage Destruction In Autoimmune Diseases (ill) NUMBER OF SEQUENCES: 7 (IV) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 ammo acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (il) MOLECULE TYPE: peptide (in) HYPOTHETICAL: NO (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1..13 (D) OTHER INFORMATION: /label= Xaa /note= "Xaa on pos 5 = A or S; Xaa on pos 7 = Q, R or G; Xaa on pos 8 = T or S; Xaa on pos 9 = V or L; Xaa on pos 10 = R or Q" (Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Ala Gly Trp Leu Xaa Asp Xaa Xaa Xaa Xaa Tyr Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 2: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 ammo acids (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (in) HYPOTHETICAL: NO Iix) FEATURE: (A) NAME/KEY: Peptide ( B ) LOCATION : 1 . . 13 (D) OTHER INFORMATION: /label= PEPTIDE /note= "Xaa on pos 5 = A or S; Xaa on pos 7 = Q, R org; Xaa on pos 8 = T or s; Xaa on pos 10 = R or Q" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Ala Gly Trp Leu Xaa Asp Xaa Xaa Leu Xaa Tyr Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 3: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: am o acid (C) STRANDEDNESS: smgle (D) TOPOLOGY: linear (i ) MOLECULE TYPE: peptide (in) HYPOTHETICAL: NO (Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Ala Gly Trp Leu Ala Asp Gin Thr Val Arg Tyr Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 4: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 ammo acids (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (111) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Ala Gly Trp Leu Ala Asp Arg Ser Val Arg Tyr Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 5: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 ammo acids (B) TYPE: ammo acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (m) HYPOTHETICAL: NO (x ) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Ala Gly Trp Leu Ala Asp Gly Ser Leu Arg Tyr Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 6: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 ammo acids (B) TYPE: amino acid (C) STRANDEDNESS: smgle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (111) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Ala Gly Trp Leu Ser Asp Gly Ser Val Gin Tyr Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 7: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 ammo acids (B) TYPE: ammo acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ill) HYPOTHETICAL: NO ( ) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Pro Lys Phe Val Lys Gin Asn Thr Leu Lys Leu Ala Thr 1 5 10

Claims: CLAIMS: 1. Peptide having 13- 5 amino acid residues characterized in that said peptide comprizes Λe amino acid sequence AGWLRj DR2R3R4R5 YPI in which Rj = A, S R 2 = Q,R,G R3=T,S R4 = V,L R 5 = R,Q wiΛ Λe provision Λat Λe peptide is not SSAGWLADRSVRYPISKARPNXGG, NAGWLSDGSVQYPΓΓKPREP, DAGWLADGHSVRYPISRPRKR, GGLDWCN AGWLSDGS VQYPITKPR OR EQLFAAYEDGFEQCDAGWLADQTVRYPIRAPRVGCY. 2. Peptide having 13-55 amino acid residues characterized in Λat said peptide comprizes at least Λe amino acid sequence AGWLR 1 DR 2 R LR 5 YPI in which R\ = A, S R 2 = Q,R,G R 3 =T,S R 5 = R,Q 3. Peptide having 13-55 amino acid residues characterized in that said peptide comprizes at least one of Λe amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI. 4. Peptide consisting of one ofthe amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI. 5. Peptide having 13-55 amino acid residues and comprizmg the amino acid sequence A GW L R] D R2 R3 R4 R5 Y P I m which R 1 = A, S, R 2 = Q, R, G, R 3 -= T, S, R4 = V, L, and R5 = R, Q, for use as a medicament. 6. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizmg Λe amino acid sequence A GWL R ] D R 2 R3 R 4 R 5 Y P I in whichR^ A, S, R 2 = Q, R, G, R 3 = T, S, R4 = V, L, andR 5 =R, Q, and a pharmaceutical acceptable carrier. 7. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing Λe amino acid sequence A GW LR] D R 2 R3 L R5 Y P I in which Rj = A, S, R 2 = Q, R, G, R3 = T, S and R 5 = R, Q, and a pharmaceutical acceptable carrier. 8. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing at least one of Λe amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI. 9. Pharmaceutical preparation comprizmg at least one of Λe peptides- AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLADGSLRYPI and AGWLSDGSVQYPI and a pharmaceutical acceptable carrier. 10. Use of a peptide having 13-55 amino acid residues, said peptide comprizing Λe amino acid sequence A G W L R] D R 2 R3 R4 R5 Y P I in which R]= A, S, R 2 = Q, R, G, R 3 = T, S, R4 = V, L, and R5 = R, Q, for Λe manufacture of a pharmaceutical preparation for use in a peptide-induced tolerance Λerapy for Λe induction of tolarance to autoaggressive T cells associated wiΛ T-cell mediated articular cartilage destruction in autoimmune diseases.

Inventors: BOOTS ANNA MARIA HELENA, VERHEIJDEN GIJSBERTUS FRANCISC, BOOTS, ANNA, MARIA, HELENA, VERHEIJDEN, GIJSBERTUS, FRANCISCUS, MARIA
Applicants: AKZO NOBEL NV, BOOTS ANNA MARIA HELENA, VERHEIJDEN GIJSBERTUS FRANCISC, AKZO NOBEL N.V., BOOTS, ANNA, MARIA, HELENA, VERHEIJDEN, GIJSBERTUS, FRANCISCUS, MARIA
Application year: 1996
Main classification: C07K14
IPC codes: A61K38, A61P37, C07K7, C07K14